Drug Profile
CH 1504
Alternative Names: CH-1504; MobileTrexLatest Information Update: 27 Jun 2014
Price :
$50
*
At a glance
- Originator University of South Alabama
- Developer Chelsea Therapeutics
- Class Antineoplastics
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S
- 22 Oct 2009 Interim efficacy and adverse events data from a phase II trial in Rheumatoid arthritis presented at the the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009)
- 18 Mar 2009 Interim efficacy & adverse events data from a phase II trial in Rheumatoid arthritis released by Chelsea Therapeutics